ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Stock Performance

IBRX stock opened at $2.73 on Monday. The stock’s 50 day simple moving average is $4.13 and its 200 day simple moving average is $4.43. The company has a market cap of $1.90 billion, a P/E ratio of -2.97 and a beta of 0.86. ImmunityBio has a fifty-two week low of $2.50 and a fifty-two week high of $10.53.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Captrust Financial Advisors bought a new position in ImmunityBio during the 3rd quarter valued at $41,000. Virtu Financial LLC bought a new position in shares of ImmunityBio during the third quarter valued at about $51,000. Algert Global LLC purchased a new position in ImmunityBio during the second quarter worth about $86,000. Mirae Asset Global Investments Co. Ltd. grew its position in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after purchasing an additional 4,545 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in ImmunityBio in the 2nd quarter valued at about $105,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.